Systematic review of health state utility values for economic evaluation of colorectal cancer

Health Economics Review

Volumn 6, Issue 1, 2016, Pages

  Jeong, Kim ^a   Cairns, John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Colorectal cancer; Economic evaluation; Health state utility value; QALY

Indexed keywords

CANCER THERAPY; COLORECTAL CANCER; COLORECTAL POLYP; COLOSTOMY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; GENE MAPPING; HEALTH STATUS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SYSTEMATIC REVIEW;

EID: 85006210708     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/s13561-016-0115-5     Document Type: Review

References (70)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–7.
2. Sung JJ, et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871–6.
3. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):553–66.
4. Best JH, et al. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res. 2010;19(3):391–400.
5. Dominitz JA, Provenzale D. Patient preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol. 1997;92(12):2171–8.
6. Hornbrook MC, et al. Complications among colorectal cancer survivors: SF-6D preference-weighted quality of life scores. Med Care. 2011;49(3):321–6.
7. Miller AR, et al. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum. 2000;43:1651–1703.
8. Ness RM, et al. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650–7.
9. Pickard AS, et al. Comparison of FACT- and EQ-5D-based utility scores in cancer. Value Health. 2012;15(2):305–11.
10. Ramsey SD, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294–303.
11. Ramsey SD, et al. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97(5):1228–34.
12. Smith DM, et al. Misremembering colostomies? Former patients give lower utility ratings than do current patients. Health Psychol. 2006;25(6):688–95.
13. Syngal S, et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. 1998;129(10):787–96.
14. Ward P, et al. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis. Journal of Geriatric Oncology. 2014;5(4):368–75.
15. Brown SR, et al. The impact of postoperative complications on long-term quality of life after curative colorectal cancer surgery. Ann Surg. 2014;259(5):916–23.
16. Downing A, et al. Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis. J Clin Oncol. 2015;33(6):616–24.
17. Hall PS, et al. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. Br J Cancer. 2015;112(5):948–56.
18. Hompes R, et al. Evaluation of quality of life and function at 1 year after transanal endoscopic microsurgery. Colorectal Dis. 2015;17(2):O54–61.
19. Jordan J, et al. Laparoscopic versus open colorectal resection for cancer and polyps: A cost-effectiveness study. Clinico Economics and Outcomes Research. 2014;6:415–22.
20. Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Palliat Nurs. 1997;3(5):275.
21. Sharma A, et al. Predictors of early postoperative quality of life after elective resection for colorectal cancer. Ann Surg Oncol. 2007;14(12):3435–42.
22. Wilson TR, Alexander DJ, Kind P. Measurement of health-related quality of life in the early follow-up of colon and rectal cancer. Dis Colon Rectum. 2006;49(11):1692–702.
23. Doornebosch PG, et al. Impact of transanal endoscopic microsurgery on functional outcome and quality of life. Int J Colorectal Dis. 2008;23(7):709–13.
24. Doornebosch PG, et al. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. Colorectal Dis. 2007;9(6):553–8.
25. Gosselink MP, et al. Quality of life after total mesorectal excision for rectal cancer. Colorectal Dis. 2006;8(1):15–22.
26. Kapidzic A, et al. Quality of life in participants of a CRC screening program. Br J Cancer. 2012;107(8):1295–301.
27. van den Brink M, et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(2):244–53.
28. Wiering B, et al. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun. 2010;31(11):938–44.
29. Wiering B, et al. Long-term global quality of life in patients treated for colorectal liver metastases. Br J Surg. 2011;98(4):565–71. discussion 571–2.
30. Wong CK, et al. Clinical correlates of health preference and generic health-related quality of life in patients with colorectal neoplasms. PLoS ONE [Electronic Resource]. 2013b;8(3): e58341
31. Wong CK, et al. Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm. Value Health. 2012;15(3):495–503.
32. Wong CK, et al. Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer. Value Health. 2013a;16(2):373–84.
33. Wong CK, et al. Responsiveness was similar between direct and mapped SF-6D in colorectal cancer patients who declined. J Clin Epidemiol. 2014;67(2):219–27.
34. Yang Y, et al. Improving the mapping of condition-specific health-related quality of life onto SF-6D score. Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2014;23(8):2343–53.
35. Boyd NF, et al. Whose utilities for decision analysis? Med Decis Making. 1990;10(1):58–67.
36. Dranitsaris G, et al. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. J Eval Clin Pract. 2012b;18(2):343–51.
37. Lee L, et al. Valuing postoperative recovery: validation of the SF-6D health-state utility. J Surg Res. 2013;184(1):108–14.
38. Mittmann N, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of national cancer institute of canada clinical trials group CO.17 Trial. J Natl Cancer Inst. 2009;101(17):1182–92.
39. Augestad K, et al. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open. 2013;3(4):e002391.
40. Hamashima C. Long-term quality of life of postoperative rectal cancer patients. Journal of Gastroenterology & Hepatology. 2002;17(5):571–6.
41. Kim SH, et al. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes. 2012;10:151.
42. Kim SH, et al. Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population. Health Qual Life Outcomes. 2014;12:145.
43. Norum J, et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol. 1997;8(1):65–70.
44. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer. 2009;101(1):12–8.
45. Smith R, et al. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Med J Aust. 1993;158:319–22.
46. Young CJ, et al. Improving Quality of Life for People with Incurable Large-Bowel Obstruction: Randomized Control Trial of Colonic Stent Insertion. Dis Colon Rectum. 2015;58(9):838–49.
47. Cheung YB, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value Health. 2009;12(2):371–6.
48. Dranitsaris G, et al. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. J Oncol Pharm Pract. 2012a;18(1):57–67.
49. Dranitsaris G, et al. Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in Malaysia. Malaysian Journal of Medical Sciences. 2011b;18(4):31–42.
50. Dranitsaris G, et al. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011a;27(1):23–30.
51. Farkkila N, et al. Health-related quality of life in colorectal cancer. Colorectal Dis. 2013;15(5):e215–22.
52. Haapamaki MM, et al. Physical performance and quality of life after extended abdominoperineal excision of rectum and reconstruction of the pelvic floor with gluteus maximus flap. Dis Colon Rectum. 2011;54(1):101–6.
53. Polat U, et al. Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: Impact of patient education before treatment initiation. Journal of Gastrointestinal Oncology. 2014;5(4):270–5.
54. Schwandner O. Sacral neuromodulation for fecal incontinence and "low anterior resection syndrome" following neoadjuvant therapy for rectal cancer. Int J Colorectal Dis. 2013;28(5):665–9.
55. Andersson J, et al. Health-related quality of life after laparoscopic and open surgery for rectal cancer in a randomized trial. Br J Surg. 2013;100(7):941–9.
56. Bennett L, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer. 2011;105(10):1495–502.
57. Carter HE, et al. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer (Oxford, England: 1990). 2014;50(3):535–43.
58. Odom D, et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011;26(2):173–81.
59. Stein D, et al. Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands. Int J Colorectal Dis. 2014;29(10):1203–10.
60. Wang J, et al. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer. 2011;104(12):1848–53.
61. Rowen D, et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health. 2011;14(5):721–31.
62. Norman R, et al. Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. Qual Life Res. 2016;25(3):637–49.
63. Longworth L, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224.
64. McKenzie L, van der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health. 2009;12(1):167–71.
65. Teckle P, et al. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health Qual Life Outcomes. 2013;11:203.
66. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.
67. Kind P, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–41.
68. NICE. Guide to the methods of technology appraisal 2013. 2013. Accessed 1 June 2013.
69. Burke MJ, Sidhu R, George E. PCN158 - Utility Values Used in National Institute for Health and Care Excellence (NICE) Technology Appraisals of Medicines for 4 Metastatic Cancers. Value Health. 2013;16(7):A420.
70. Glaser AW, et al. Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey. BMJ Open. 2013;3:e002317.